Helicobacter pylori – Resistenzspektrum in Deutschland und Bedeutung für die Differenzialtherapie

Wolfgang Fischbach

Publication History

Article published online:
30 April 2020

• Literatur

• 1 Fischbach W, Malfertheiner P, Lynen Jansen P. et al. S2k-Leitlinie H. pylori und gastroduodenale Ulkuskrankheit. Z Gastroenterol 2016; 54: 327-363
• 2 Fischbach W, Malfertheiner P, Hoffmann JC. et al. S3-guideline „helicobacter pylori and gastroduodenal ulcer disease“ of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e.V., German society for rheumatology, AWMF-registration-no. 021/001. Z Gastreoenterol 2009; 47: 1230-1263
• 3 LI BZ, Threapleton DE, Wang JY. et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ 2015; 351: h4052
• 4 Megraud F, Coenen S, Versporten A. et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42
• 5 Bluemel B, Goelz H, Goldmann B. et al. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018. Clin Microbiol Infect 2019; DOI: doi.org/10.1016/j.cmi.2019,06.007.
• 6 Yeo YH, Shiu SI, Ho HJ. et al. First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut 2017; 67: 20-27
• 7 McFarland LV, Huang Y, Wang L. et al. Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J 2016; 4: 546-561